2025
P-1503. Dual β-Lactam Approach for Treatment of Mycobacterium abscessus Infections in Adults – Results in 19 Patients
Kalyatanda G, Dousa K, Lyons H, Mardourian M, Rhodes J, Iakovidis A, El-Helou G, Wilson B, Daley C, Holland S, Kreiswirth B, Nguyen D, Shin E, Kurz S, Johnson J, Bonomo R. P-1503. Dual β-Lactam Approach for Treatment of Mycobacterium abscessus Infections in Adults – Results in 19 Patients. Open Forum Infectious Diseases 2025, 12: ofae631.1672. PMCID: PMC11778049, DOI: 10.1093/ofid/ofae631.1672.Peer-Reviewed Original ResearchSubspecies abscessusB-lactamAssociated with high cure ratesIn vitro susceptibility resultsMulti-drug regimensCurrent treatment regimensSolid organ transplantationHigh cure ratesTime to initiationOptimize treatment outcomesMab infectionSynergy testClinical cureImmunocompromised patientsPulmonary infectionDiscontinued treatmentTreatment regimensCase reportClinical outcomesCure rateImmunocompromised individualsAutoimmune diseasesTreatment successEarly treatmentCulture conversion
2024
Cryptosporidiosis in individuals with inflammatory bowel disease: a scoping review protocol
Liu B, Schnider A, DeArmond M, Banach D, Haubrich B. Cryptosporidiosis in individuals with inflammatory bowel disease: a scoping review protocol. BMJ Open 2024, 14: e086529. PMID: 39414295, PMCID: PMC11481120, DOI: 10.1136/bmjopen-2024-086529.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseJoanna Briggs InstituteBowel diseaseAssociated with significant morbidityModerate-to-severe diarrheaPublished clinical literatureTreatment of cryptosporidiosisPeer-reviewed journalsImmunosuppressive therapyInstitutional review boardRisk of infectionSignificant morbidityImmunocompromised individualsTheses GlobalCrohn's diseaseGastrointestinal infectionsGrey literatureReview protocolRisk factorsAdult studiesCochrane LibrarySelf-limitingPatientsEpidemiological correlationReview teamThe respiratory syncytial virus vaccines are here: Implications for solid organ transplantation
Trubin P, Azar M, Kotton C. The respiratory syncytial virus vaccines are here: Implications for solid organ transplantation. American Journal Of Transplantation 2024, 24: 897-904. PMID: 38341028, DOI: 10.1016/j.ajt.2024.02.003.Peer-Reviewed Original ResearchRespiratory syncytial virusSolid organ transplantationLower respiratory tract diseaseHigh risk of infectious complicationsBurden of RSV diseaseOrgan transplantationRisk of infectious complicationsRespiratory syncytial virus vaccineRespiratory tract diseaseCenters for Disease Control and Prevention's Advisory CommitteeOrgan transplant recipientsSolid organ recipientsPoor clinical outcomesFood and Drug AdministrationRSV F glycoproteinRespiratory virus vaccinesRSV diseaseInfectious complicationsTransplant recipientsClinical outcomesSyncytial virusClinical decision-makingImmunocompromised individualsOrgan recipientsImmunization PracticesPersistent SARS-CoV-2 infection: significance and implications
Machkovech H, Hahn A, Garonzik Wang J, Grubaugh N, Halfmann P, Johnson M, Lemieux J, O'Connor D, Piantadosi A, Wei W, Friedrich T. Persistent SARS-CoV-2 infection: significance and implications. The Lancet Infectious Diseases 2024, 24: e453-e462. PMID: 38340735, DOI: 10.1016/s1473-3099(23)00815-0.Peer-Reviewed Original ResearchPersistent SARS-CoV-2 infectionSARS-CoV-2 infectionSuboptimal immune responsesPre-existing immunityPersistent virus replicationMonitoring viral evolutionPublic health problemTissue reservoirsImmunocompromised individualsTreatment strategiesPersistent infectionPublic health priorityImmune responseSARS-CoV-2 replicationSARS-CoV-2Virus replicationInfectionVirus variantsViral evolutionHealth priorityHealth problemsTreatmentPathophysiologyPatientsDiagnosis
2023
Epstein-Barr virus–associated primary intracranial leiomyosarcoma in an immunocompetent patient: illustrative case
Tabor J, Lei H, Morales-Valero S, O’Brien J, Gopal P, Erson-Omay E, Fulbright R, Moliterno J. Epstein-Barr virus–associated primary intracranial leiomyosarcoma in an immunocompetent patient: illustrative case. Journal Of Neurosurgery Case Lessons 2023, 5: case22532. PMID: 36692065, PMCID: PMC10550697, DOI: 10.3171/case22532.Peer-Reviewed Original ResearchEpstein-Barr virusPrimary intracranial leiomyosarcomaHuman immunodeficiency virusImmunocompetent statusImmunocompetent patientsIntracranial leiomyosarcomaMainstay of treatmentGross total resectionLeft-sided headacheSmooth muscle tumorsLeft middle cranial fossaMagnetic resonance imagingMiddle cranial fossaDura-based massUncomplicated resectionPrompt diagnosisTotal resectionAssociated edemaImmunodeficiency virusPoor prognosisMuscle tumorsRare diagnosisRare tumorImmunocompromised individualsPatients
2020
Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas
Leeman-Neill RJ, Soderquist CR, Montanari F, Raciti P, Park D, Radeski D, Mansukhani MM, Murty VV, Hsiao S, Alobeid B, Bhagat G. Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas. Haematologica 2020, 107: 201-210. PMID: 33297669, PMCID: PMC8719101, DOI: 10.3324/haematol.2020.267294.Peer-Reviewed Original ResearchConceptsPlasmablastic lymphomaJAK/STATSolid organ allograft recipientsTargetable oncogenic pathwaysOrgan allograft recipientsAllograft recipientsComprehensive histopathologicEBV infectionHIV infectionPlasmablastic myelomaClinical outcomesClinicopathologic featuresYears postdiagnosisAggressive neoplasmDisease subsetsEBV- casesImmunophenotypic heterogeneityImmunophenotypic evaluationMAP kinaseImmunocompromised individualsMYC rearrangementDisease pathogenesisPhenotypic spectrumNotch pathway genesOncogenic pathwaysManagement strategies for human babesiosis
Smith RP, Hunfeld KP, Krause PJ. Management strategies for human babesiosis. Expert Review Of Anti-infective Therapy 2020, 18: 625-636. PMID: 32268823, DOI: 10.1080/14787210.2020.1752193.Peer-Reviewed Original ResearchConceptsHuman babesiosisSevere diseaseImmunocompromised individualsCurrent treatment recommendationsHard-bodied ticks
2018
Prototheca zopfii Colitis in Inherited CARD9 Deficiency
Sari S, Dalgic B, Muehlenbachs A, DeLeon-Carnes M, Goldsmith CS, Ekinci O, Jain D, Keating MK, Vilarinho S. Prototheca zopfii Colitis in Inherited CARD9 Deficiency. The Journal Of Infectious Diseases 2018, 218: 485-489. PMID: 29659908, PMCID: PMC6049027, DOI: 10.1093/infdis/jiy198.Peer-Reviewed Original ResearchConceptsCARD9 deficiencyInherited CARD9 DeficiencySpecific immune defectsAbdominal painImmune defectsBloody diarrheaImmunocompromised individualsExome sequencingHuman protothecosisConsanguineous unionsProtothecosisNew mechanistic insightsFrameshift mutationDeficiencyPancolitisColitisPainDiarrheaPatientsPrototheca zopfiiImmunodeficiencyCARD9InfectionImmunityMonthsIntranasal Immunization with DnaK Protein Induces Protective Mucosal Immunity against Tuberculosis in CD4-Depleted Mice
Chuang YM, Pinn ML, Karakousis PC, Hung CF. Intranasal Immunization with DnaK Protein Induces Protective Mucosal Immunity against Tuberculosis in CD4-Depleted Mice. Frontiers In Cellular And Infection Microbiology 2018, 8: 31. PMID: 29473022, PMCID: PMC5809501, DOI: 10.3389/fcimb.2018.00031.Peer-Reviewed Original ResearchMeSH KeywordsAdenosine TriphosphatasesAdministration, IntranasalAnimalsAntibodies, BacterialAntigens, BacterialBacterial ProteinsBCG VaccineCD4-Positive T-LymphocytesCross ReactionsCytokinesDisease Models, AnimalFemaleImmunity, MucosalImmunizationLymphocyte DepletionMiceMolecular ChaperonesMycobacterium tuberculosisNasal MucosaTuberculosisTuberculosis VaccinesConceptsBacillus Calmette-GuérinIntranasal vaccinationT cellsMucosal immunityProtective immunityVaccine candidatesTissue-resident CD4Different immune statusProtective mucosal immunityNew vaccine candidatesGlobal health challengeResident CD4BCG vaccinationIntranasal immunizationMtb infectionImmune statusImmunocompetent miceDNA vaccineBCG vaccineC57BL/6J miceCalmette-GuérinAvailable vaccinesImmunocompromised individualsLimited efficacyCD4
2016
Mood stabilizers inhibit cytomegalovirus infection
Ornaghi S, Davis JN, Gorres KL, Miller G, Paidas MJ, van den Pol AN. Mood stabilizers inhibit cytomegalovirus infection. Virology 2016, 499: 121-135. PMID: 27657833, PMCID: PMC5102808, DOI: 10.1016/j.virol.2016.09.012.Peer-Reviewed Original ResearchConceptsCytomegalovirus infectionAvailable anti-CMV drugsAnti-CMV drugsCommon infectious causeCongenital birth defectsInfected newbornsFetal exposureInfectious causesInfected fetusesMood stabilizersMouse CMVMood disordersImmunocompromised individualsPsychiatric disordersBody weightViral resistanceHuman CMVDevelopmental maturationBirth defectsSpecific inhibitionCMVInfectionValnoctamideDisordersDrugs
2015
Cervicofacial necrotizing fasciitis caused by Haemophilus influenzae serotype e in a patient with Sjogren's syndrome, systemic lupus erythematosus and hypocomplementaemia
Azar M, Folk D, Henderson T, Mehra S, Vining E, Banach D. Cervicofacial necrotizing fasciitis caused by Haemophilus influenzae serotype e in a patient with Sjogren's syndrome, systemic lupus erythematosus and hypocomplementaemia. JMM Case Reports 2015, 2 DOI: 10.1099/jmmcr.0.000040.Peer-Reviewed Case Reports and Technical NotesSystemic lupus erythematosusNecrotizing fasciitisH. influenzaeSjogren's syndromeLupus erythematosusInvasive diseaseHaemophilus influenzae serotype eInvasive H. influenzae infectionsSerotype E.Cervicofacial necrotizing fasciitisMonomicrobial necrotizing fasciitisCervical necrotizing fasciitisH. influenzae infectionsBroad-spectrum antibioticsAdditional debridementB vaccinationEmergent debridementNeck painInfluenzae infectionIntraoperative culturesBlood culturesClinical dataImmunocompromised individualsFasciitisClinical importancePhase 1 Randomized, Double-Blind, Placebo-Controlled Study of RG7667, an Anticytomegalovirus Combination Monoclonal Antibody Therapy, in Healthy Adults
Ishida JH, Burgess T, Derby MA, Brown PA, Maia M, Deng R, Emu B, Feierbach B, Fouts AE, Liao XC, Tavel JA. Phase 1 Randomized, Double-Blind, Placebo-Controlled Study of RG7667, an Anticytomegalovirus Combination Monoclonal Antibody Therapy, in Healthy Adults. Antimicrobial Agents And Chemotherapy 2015, 59: 4919-4929. PMID: 26055360, PMCID: PMC4505204, DOI: 10.1128/aac.00523-15.Peer-Reviewed Original ResearchConceptsHealthy adultsPlacebo groupAdverse eventsMonoclonal antibodiesDose-proportional pharmacokineticsMost adverse eventsDose-escalation studyMonoclonal antibody therapyProportion of subjectsHuman monoclonal antibodyOverall pharmacokinetic profileLife-threatening diseasePhase 1Transplant recipientsCytomegalovirus infectionAntibody therapyImmunogenicity profileMultiple dosesAntibody responseImmunocompromised individualsPharmacokinetic profileSusceptible populationAdultsHost targetsTherapy
2009
Update on Babesiosis
Vannier E, Krause PJ. Update on Babesiosis. Interdisciplinary Perspectives On Infectious Diseases 2009, 2009: 984568. PMID: 19727410, PMCID: PMC2734943, DOI: 10.1155/2009/984568.Peer-Reviewed Original ResearchTick-borne infectious diseaseHuman babesiosisBlood safety riskSpecific antimicrobial therapyMultiple prevention strategiesFulminant diseaseThin blood smearsClinical featuresExchange transfusionModerate illnessImmunosuppressive drugsAsymptomatic infectionDefinitive diagnosisAsymptomatic carriersAntimicrobial therapyConvalescent seraSevere diseaseImmunocompromised individualsHigh riskSevere casesEndemic areasPrevention strategiesBabesia antibodiesHealthy adultsInfection rangeNovel Biomarkers for the Diagnosis of Urinary Tract Infection–-A systematic Review
Nanda N, Juthani-Mehta M. Novel Biomarkers for the Diagnosis of Urinary Tract Infection–-A systematic Review. Biomarker Insights 2009, 4: bmi.s3155. PMID: 19707519, PMCID: PMC2729697, DOI: 10.4137/bmi.s3155.Peer-Reviewed Original ResearchLower urinary tract infectionsUrinary tract infectionClinical presentationNovel biomarkersTract infectionsElevated serum procalcitonin levelsKidney transplant recipientsSerum procalcitonin levelsPediatric age groupExtremes of ageTime of presentationSpinal cord injuryClinical management decisionsPaucity of dataAsymptomatic bacteriuriaProcalcitonin levelsTransplant recipientsAggressive treatmentSignificant morbidityUrine cultureCord injuryInterleukin-6High prevalenceImmunocompromised individualsDiagnostic criteria
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply